Skip to Content Facebook Feature Image

LIV Golf players face another deadline with their future in golf at stake

Sport

LIV Golf players face another deadline with their future in golf at stake
Sport

Sport

LIV Golf players face another deadline with their future in golf at stake

2026-10-13 21:46 Last Updated At:10-14 00:31

For the second time in nine months, players who took the Saudi riches of LIV Golf are facing a tight deadline on their future. The first was a lot easier to ignore.

Brooks Koepka in January became the first LIV player to return to the PGA Tour under financial penalties that included no access to equity grants for five years. CEO Brian Rolapp then offered the same deal to Jon Rahm, Bryson DeChambeau and Cameron Smith.

They had three weeks to decide and none took it. Why should they? The United States was not at war with Iran. Saudi Arabia's sovereign wealth fund was still pumping cash — more than $5 billion and counting — into the LIV Golf League. They were rich and getting richer.

The deadline set by the European tour this week is far more daunting.

As LIV is trying to emerge from bankruptcy without Saudi funding, European tour CEO Guy Kinnings delivered a “take it or leave it” ultimatum to anyone seeking a home on his circuit — take up membership, but only if they leave the new version of LIV Golf.

“Players need to make a choice,” Kinnings said. "We have rules and regulations which are there to protect our tour and which our members must all abide by. Players who are not willing to comply with our rules and regulations should not be seeking to join our tour.”

They have three weeks to decide.

European tour membership is the best alternative because the PGA Tour bans players for one year dating to their last LIV event. Those who want European membership have to disclose where they plan to play in 2027, and if that includes LIV 2.0, there's no need to apply.

For European-born players — Tyrrell Hatton of England, Thomas Detry of Belgium and Spaniards David Puig and Josele Ballester come to mind — no membership means no chance at playing in the Ryder Cup.

Jon Rahm already has made clear he is leaving LIV after reviewing the proposed terms of LIV 2.0. The prize funds are no longer $20 million. The schedule is 10 tournaments, leaving plenty of weeks to play elsewhere, except that the PGA Tour and now the European tour are not options. Maybe they still have their MENA Tour cards.

Scott O'Neil, the CEO at LIV Golf, has been preaching “complete, not compete,” as a way of saying tours around the world should all work together. This is a different message his predecessor, Greg Norman, had in 2022 when LIV Golf launched by spending more than $1 billion to lure away stars who couldn't ignore the money.

“This is an opportunity to start a movement that will change the course of history by bringing new and open competition to the sport we all love," Norman said.

Saudi-backed LIV was a threat that thrived on disruption. Bankruptcy LIV wants cooperation.

BC Partners Credit has pledged $300 million for LIV 2.0 to move forward. The amended restructuring support agreement has moved the deadline to Oct. 25 to secure a “critical mass of players sufficient to operate a bona fide professional golf league.”

That's up to BC Partners to decide how many players — and who they are — can satisfy the requirement. And it can extend the deadline so it can move on with restructuring.

But it's a bleak future, certainly not as appealing as it was when LIV was burning through Saudi cash to tempt players to leave. Now the carrot is equity ownership in a league coming out of bankruptcy amid concerns everyone might jump ship.

And then where do they swim? The European tour made its position clear. Rolapp, meanwhile, said in January there was no guarantee the program that brought Koepka back would be available again. He is guided by what's best for the PGA Tour. He also answers to a membership that stayed put when so many others were chasing generational wealth.

“There are 225 guys with tour cards,” Xander Schauffele said last week in Japan. “And if you sat down and interviewed all of them, you’re going to get probably three or four boxes of how guys feel. Some guys don’t care, some guys are really ticked off, some guys want them to have a huge fine, some guys would let them back tomorrow.”

Rolapp said in August the tour is built on players earning their place, it's a membership organization that has rules and rules only matter if they're enforced.

The PGA Tour, trying to sort out final details of the new competition model for 2028 (where and when to play and who's going to pay for it), also has to consider a path back for the stars it lost who undoubtedly would make the tour better.

O'Neil and Ted Goldthorpe, partner and head of BC Partners Credit, remain bullish on their path out of bankruptcy and into a future that appears as clear as haar on the East Lothian coast of Scotland.

Goldthorpe was at the Sportico Invest London conference last week when he spoke to the financial sustainability of LIV 2.0.

“A lot of the money that was spent created the ecosystem and infrastructure that exists today,” he said. “We think we can run this in a financially sustainable way because much of that spending went to getting the players, and the players are here.”

But are they staying? The clock is ticking.

See AP’s full golf coverage here

FILE - Captain Jon Rahm of Legion XIII celebrates after putting on the 18th hole green during the final round of HSBC LIV Golf Hong Kong at Hong Kong Golf Club Fanling, Sunday, March 8, 2026 in Hong Kong. (Mike Stobe/LIV Golf via AP, File)

FILE - Captain Jon Rahm of Legion XIII celebrates after putting on the 18th hole green during the final round of HSBC LIV Golf Hong Kong at Hong Kong Golf Club Fanling, Sunday, March 8, 2026 in Hong Kong. (Mike Stobe/LIV Golf via AP, File)

FILE - Captain Jon Rahm of Legion XIII reads his putt during the final round of LIV Golf Bedminster at Trump National Golf Club on Sunday, Aug. 9, 2026 in Bedminster, N.J. (Montana Pritchard/LIV Golf, File)

FILE - Captain Jon Rahm of Legion XIII reads his putt during the final round of LIV Golf Bedminster at Trump National Golf Club on Sunday, Aug. 9, 2026 in Bedminster, N.J. (Montana Pritchard/LIV Golf, File)

ZURICH, Switzerland--(BUSINESS WIRE)--Oct 14, 2026--

AL-S Pharma AG (“AL-S Pharma” or “the Company”), a clinical-stage biotechnology company discovering and developing human antibodies that target misfolded proteins implicated in amyotrophic lateral sclerosis (ALS), today announced the appointment of Harry Welten as chief executive officer (CEO). Mr. Welten succeeds Michael Salzmann, Ph.D. The Company recently reported positive topline results from a Phase 2 study of its lead program AP-101, a human monoclonal antibody targeting misfolded superoxide dismutase 1 (SOD1). AL-S Pharma is currently advancing AP-101 toward a confirmatory Phase 3 clinical trial in ALS which it aims to initiate in 2027.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261013851910/en/

“As AP-101 enters its confirmatory study, we are delighted to welcome Harry to AL-S Pharma. Harry has spent his career building life sciences companies, both as CFO and as chairman setting strategy at the board level, and has a proven record of securing the financing and partnerships needed to advance clinical programs. The board is confident that his strategic and financial leadership is what AL-S Pharma needs to take AP-101 through Phase 3 and toward regulatory approval, so that it can become available to people living with ALS,” said Hubert Birner, Ph.D., chairman of AL-S Pharma. “On behalf of the board, I would also like to thank Michael for his leadership. During his tenure, the Company advanced AP-101 from early development to a Phase 3-ready program.”

“AL-S Pharma has reached a pivotal stage in the development of AP-101, and I have great respect for what the team has built over the past decade. I look forward to working with the board, the leadership team, and our clinical and scientific partners to build on this strong foundation,” said Mr. Welten. “As AP-101 advances into Phase 3, my priorities will be to execute the Phase 3 program with rigor, on time and on budget, and to secure the financing and strategic partnerships required to bring AP-101 through regulatory approval to patients. Above all, I am committed to contributing to the well-being of people living with ALS and their families, who urgently need new treatment options.”

Mr. Welten is a board-level executive with more than 25 years of chief financial officer (CFO) and chairman experience in the life sciences industry across Europe and the United States. He has guided companies through growth, restructuring, financings, M&A, and commercialization, and has raised more than CHF 500 million through venture capital, IPOs, follow-on offerings, PIPE financings, and convertible instruments. He has led or supported more than eight M&A, public-market, and strategic transactions including the largest European IPO of 2005.

With more than 15 years of board experience, Mr. Welten served on 14 life sciences, medtech, and AI diagnostics boards in Switzerland, across Europe, and in the United States, seven of them as chairman, and has chaired both audit and finance committees and nomination and compensation committees. As chairman, he guided Biognosys, Aidence, and Proteomedix through to their sale or merger with Nasdaq-listed companies. He currently serves as chairman of b-rayZ AG and as a board member of Lumendi AG. Mr. Welton holds an MBA with honors from Columbia Business School, a degree in business administration and economics from the Zurich School of Management, as well as a federal degree in banking and finance from the KV Business School Zurich.

About AL-S Pharma AG

AL-S Pharma is a clinical-stage biotech company developing AP-101 for the treatment of amyotrophic lateral sclerosis (ALS). Founded and co-owned by Neurimmune and TVM Capital Life Science, AL-S Pharma brings together a seasoned team of biotech and pharmaceutical leaders with expertise spanning drug discovery, translational research, and clinical development. AL-S Pharma is based in Zurich, Switzerland. For more information, visit www.al-spharma.com.

Harry Welten, CEO, AL-S Pharma AG

Harry Welten, CEO, AL-S Pharma AG

Recommended Articles